Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Trisalus Life Sciences Inc (TLSI)

$2.52 -0.15 (-5.62%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	163.69M
Revenue (ttm)	45.15M
Net Income (ttm)	-39.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-86.89%
Debt to Equity Ratio	-0.98

Volume	1,617,400
Avg Vol	327,134
Day's Range	N/A - N/A
Shares Out	61.31M
Stochastic %K	13%
Beta	0.56
Analysts	Strong Sell
Price Target	$9.20

Company Profile

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; an...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 321 5212

Website: trisaluslifesci.com

Address:

6272 West 91st Avenue, Westminster, United States

Axielg May. 14 at 10:55 PM

$TLSI this 44% drop seems abit excessive based solely on the missed quarterly revenue estimates. This is set for a correction.

0 · Reply

focafoca99 May. 14 at 8:14 PM

$TLSI held its annual meeting, electing two directors, ratifying Grant Thornton as auditor and approving an advisory vote on executive

0 · Reply

willem May. 14 at 5:53 PM

$TLSI stock raid for pennies.

0 · Reply

willem May. 14 at 5:44 PM

$TLSI What happened at 12:46???

0 · Reply

rapidtrades May. 14 at 4:32 PM

$TLSI buying more before the power hour

0 · Reply

rapidtrades May. 14 at 1:41 PM

$TLSI bouncing back up folks !

0 · Reply

Gemology May. 13 at 8:43 PM

$CGTL $TLSI $FATN $NPWR $JZXN park

0 · Reply

rapidtrades May. 13 at 5:48 PM

$TLSI pointing upward

0 · Reply

HUBIE_DUBOIS May. 13 at 5:15 PM

$TLSI Sold at 2.64 for just under 18% profit. Very happy with the profit and hope everyone else still in their trade make some $$$$. Tought "work day"! I love what I do!

1 · Reply

rapidtrades May. 13 at 4:46 PM

$TLSI get ready for lift off

0 · Reply

TriSalus Life Sciences price target lowered to $8 from $10 at Lake Street

2026-05-12T22:14:02.000Z - 2 days ago

TriSalus Life Sciences reports Q EPS 3c, one estimate (16c)

May 12, 2026, 4:30 PM EDT - 2 days ago

TriSalus Life Sciences Earnings Call Transcript: Q1 2026

May 12, 2026, 4:01 PM EDT - 2 days ago

TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth

2026-05-12T16:00:15.000Z - 2 days ago

TriSalus announces journal publication of PEDD study

May 12, 2026, 8:00 AM EDT - 2 days ago

Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance

May 4, 2026, 5:24 PM EDT - 10 days ago

TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors

Apr 28, 2026, 4:05 PM EDT - 16 days ago

TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call

Apr 9, 2026, 4:05 PM EDT - 5 weeks ago

TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting

2026-04-07T13:41:02.000Z - 5 weeks ago

TriSalus Life Sciences appoints Marshall as Chief Medical Officer

Apr 7, 2026, 9:15 AM EDT - 5 weeks ago

TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer

2026-03-23T13:17:40.000Z - 7 weeks ago

TriSalus Life Sciences price target lowered to $8 from $12.50 at Northland

Mar 18, 2026, 8:00 AM EDT - 2 months ago

TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models

2026-03-06T11:55:11.000Z - 2 months ago

TriSalus Life Sciences price target lowered to $7 from $12 at Canaccord

Mar 5, 2026, 4:30 PM EST - 2 months ago

TriSalus Life Sciences Earnings Call Transcript: Q4 2025

2026-03-05T21:11:39.000Z - 2 months ago

TriSalus Life Sciences sees FY26 revenue $60M-$62M, consensus $60.34M

2026-03-05T21:05:24.000Z - 2 months ago

TriSalus Life Sciences reports Q4 EPS (21c), consensus (14c)

Mar 5, 2026, 4:01 PM EST - 2 months ago

TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance

Feb 25, 2026, 4:05 PM EST - 2 months ago

TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call

2026-02-20T14:23:30.000Z - 2 months ago

TriSalus Life Sciences 9.76M share Spot Secondary priced at $4.10

Feb 20, 2026, 8:00 AM EST - 2 months ago

TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering

2026-02-19T21:06:06.000Z - 3 months ago

TriSalus Life Sciences announces common stock offering, no amount given

Feb 19, 2026, 4:01 PM EST - 3 months ago

TriSalus Life Sciences Proposes Public Offering

2026-02-09T14:10:56.000Z - 3 months ago

TriSalus Life Sciences appoints Stansky to board of directors

Feb 9, 2026, 9:00 AM EST - 3 months ago

TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

2026-01-12T12:12:59.000Z - 4 months ago

TriSalus Life Sciences sees FY26 revenue $60M-$62M, consensus $63.77M

2026-01-12T12:05:59.000Z - 4 months ago

TriSalus Life Sciences reports preliminary Q4 revenue $13.2M, consensus $12.68M

Jan 12, 2026, 7:00 AM EST - 4 months ago

TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

2026-01-08T14:35:32.000Z - 4 months ago

TriSalus Life Sciences named a 2026 Top Pick at Northland

2025-12-17T12:25:53.000Z - 5 months ago

TriSalus Life Sciences price target raised to $12 from $11 at Canaccord

Dec 15, 2025, 2:00 PM EST - 5 months ago

TriSalus Life Sciences Transcript: KOL Event

Dec 4, 2025, 4:01 PM EST - 5 months ago

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025

Dec 2, 2025, 3:10 PM EST - 5 months ago

TriSalus Life Sciences Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 2:30 PM EST - 6 months ago

TriSalus Life Sciences Transcript: CG MedTech, Diagnostics and Digital Health & Services Forum

Nov 18, 2025, 8:00 AM EST - 6 months ago

TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™

2025-11-13T21:46:39.000Z - 6 months ago

TriSalus Life Sciences files $150M mixed securities shelf

Nov 13, 2025, 4:30 PM EST - 6 months ago

TriSalus Life Sciences Earnings Call Transcript: Q3 2025

2025-11-13T21:05:42.000Z - 6 months ago

TriSalus Life Sciences reports Q3 EPS (96c) vs (12c) last year

Nov 13, 2025, 4:01 PM EST - 6 months ago

TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance

Nov 12, 2025, 10:00 AM EST - 6 months ago

TriSalus Life Sciences Transcript: KOL Event

Nov 11, 2025, 4:05 PM EST - 6 months ago

TriSalus Life Sciences to Participate in Upcoming Investor Conferences

Nov 10, 2025, 8:00 AM EST - 6 months ago

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025

Oct 30, 2025, 8:00 AM EDT - 7 months ago

TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call

Sep 5, 2025, 9:35 AM EDT - 8 months ago

TriSalus Life Sciences Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 8:00 AM EDT - 9 months ago

TriSalus Life Sciences to Participate in Upcoming September Investor Conferences

Aug 12, 2025, 4:30 PM EDT - 9 months ago

TriSalus Life Sciences Earnings Call Transcript: Q2 2025

2025-08-12T20:05:58.000Z - 9 months ago

TriSalus Life Sciences reports Q2 EPS (27c), consensus (22c)

2025-08-12T20:05:51.000Z - 9 months ago

TriSalus Life Sciences backs FY25 revenue growth view up 50%

Aug 12, 2025, 4:01 PM EDT - 9 months ago

TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance

2025-08-11T12:25:25.000Z - 9 months ago

TriSalus publishes Pressure-Enabled Drug Delivery technology results

Aug 11, 2025, 8:00 AM EDT - 9 months ago

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

Jul 30, 2025, 4:05 PM EDT - 10 months ago

TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:05 PM EDT - 10 months ago

TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call

Jul 24, 2025, 5:58 PM EDT - 10 months ago

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock

Jun 23, 2025, 5:30 PM EDT - 11 months ago

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

Jun 4, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System

May 30, 2025, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

May 15, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Earnings Call Transcript: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

May 12, 2025, 4:30 PM EDT - 1 year ago

TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

Apr 30, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

Mar 27, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Earnings Call Transcript: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

Mar 26, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

Mar 6, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

Feb 3, 2025, 4:05 PM EST - 1 year ago

TriSalus Life Sciences Announces Key Appointments to Board of Directors

Feb 3, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

Jan 23, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

Jan 9, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

Nov 14, 2024, 9:00 AM EST - 1 year ago

TriSalus Life Sciences Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

Nov 11, 2024, 7:00 AM EST - 1 year ago

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

Nov 7, 2024, 7:00 AM EST - 1 year ago

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

Oct 31, 2024, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

Oct 17, 2024, 12:30 PM EDT - 1 year ago

TriSalus Life Sciences Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 14, 2024, 4:05 PM EDT - 1 year ago

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 26, 2024, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

Sep 23, 2024, 7:00 AM EDT - 1 year ago

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

Aug 15, 2024, 9:00 AM EDT - 1 year ago

TriSalus Life Sciences Earnings Call Transcript: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 1 year ago

TriSalus Reports Q2 2024 Financial Results and Business Update

Aug 1, 2024, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

Jul 1, 2024, 4:00 PM EDT - 2 years ago

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

Jun 26, 2024, 5:45 PM EDT - 2 years ago

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

Axielg May. 14 at 10:55 PM

$TLSI this 44% drop seems abit excessive based solely on the missed quarterly revenue estimates. This is set for a correction.

0 · Reply

focafoca99 May. 14 at 8:14 PM

$TLSI held its annual meeting, electing two directors, ratifying Grant Thornton as auditor and approving an advisory vote on executive

0 · Reply

willem May. 14 at 5:53 PM

$TLSI stock raid for pennies.

0 · Reply

willem May. 14 at 5:44 PM

$TLSI What happened at 12:46???

0 · Reply

rapidtrades May. 14 at 4:32 PM

$TLSI buying more before the power hour

0 · Reply

rapidtrades May. 14 at 1:41 PM

$TLSI bouncing back up folks !

0 · Reply

Gemology May. 13 at 8:43 PM

$CGTL $TLSI $FATN $NPWR $JZXN park

0 · Reply

rapidtrades May. 13 at 5:48 PM

$TLSI pointing upward

0 · Reply

HUBIE_DUBOIS May. 13 at 5:15 PM

$TLSI Sold at 2.64 for just under 18% profit. Very happy with the profit and hope everyone else still in their trade make some $$$$. Tought "work day"! I love what I do!

1 · Reply

rapidtrades May. 13 at 4:46 PM

$TLSI get ready for lift off

0 · Reply

Gunnar1 May. 13 at 4:35 PM

$TLSI Starter for me here

0 · Reply

rapidtrades May. 13 at 4:32 PM

$TLSI headed for recovery folks

0 · Reply

stklover May. 13 at 3:52 PM

$TLSI Maybe they should take that money they raised awhile ago and buy back their stock🤣

0 · Reply

rapidtrades May. 13 at 3:39 PM

$TLSI Bouncing back up after lunch NY time

0 · Reply

stklover May. 13 at 3:01 PM

$TLSI Stock down 65% this year. I thought bottom was in on the previous quarter and I took a nice position. Now I get hammered. I’ll buy more here, wait about 3-days, and buy more then. Delay in FDA main reason why stock is down.

0 · Reply